Reperfusion injury: Does it exist?

Journal of Molecular and Cellular Cardiology

Volumn 42, Issue 1, 2007, Pages 12-18

  Gross, Garrett J ^a   Auchampach, John A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Adenosine; Heart; Ischemia reperfusion; Opioids; Postconditioning; Reperfusion injury

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 MORPHOLINO 8 PHENYLCHROMONE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDRO 2 FURYL) 9H PURIN 2 YL] 2 PROPYNYL]CYCLOHEXANECARBOXYLIC ACID METHYL ESTER; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; 6 ETHYL 4 PROPYL 2 PHENYL 3 PYRIDINECARBOXYLIC ACID 5 THIOCARBOXYLIC ACID 5 ETHYL 3 PROPYL ESTER; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; 8 (4 SULFOPHENYL)THEOPHYLLINE; ADENOSINE; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; CP 602903; DELTA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; MORPHINE; MRS 1334; NALOXONE; NALTRINDOLE; NORBINALTORPHIMINE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; RAPAMYCIN; REPERFUSION INJURY SALVAGE KINASE; S6 KINASE; S6 KINASE INHIBITOR; WORTMANNIN;

BRADYCARDIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG POTENCY; DRUG RECEPTOR BINDING; HEART BLOCK; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTENSION; ISCHEMIC PRECONDITIONING; NONHUMAN; POSTCONDITIONING; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADENOSINE; ANIMALS; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; LIGANDS; MODELS, CARDIOVASCULAR; MYOCARDIAL REPERFUSION INJURY; RECEPTORS, OPIOID; RECEPTORS, PURINERGIC P1;

EID: 33845675393     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.09.009     Document Type: Review

References (50)

1. Gross E.R., and Gross G.J. Ligand triggers of classical preconditioning and postconditioning. Cardiovasc. Res. 70 (2006) 212-221
2. Ely S.W., and Berne R.M. Protective effects of adenosine in myocardial ischemia. Circulation 85 (1992) 893-904
3. Vinten-Johansen J., Thourani V.H., Ronson R.S., Jordan J.E., Zhao Z.Q., Nakamura M., et al. Broad-spectrum cardioprotection with adenosine. Ann. Thorac. Surg. 68 (1999) 1942-1948
4. Zhao Z.Q., and Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc. Res. 70 (2006) 200-211
5. Vinten-Johansen J., Zhao Z.Q., Jiang R., and Zatta A.J. Myocardial protection in reperfusion with postconditioning. Expert. Rev. Cardiovasc. Ther. 3 (2005) 1035-1045
6. Hausenloy D.J., and Yellon D.M. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc. Res. 61 (2004) 448-460
7. Olafsson B., Forman M.B., Puett D.W., Pou A., Cates C.U., Friesinger G.C., et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 76 (1987) 1135-1145
8. Homeister J.W., Hoff P.T., Fletcher D.D., and Lucchesi B.R. Combined adenosine and lidocaine administration limits myocardial reperfusion injury. Circulation 82 (1990) 595-608
9. Babbitt D.G., Virmani R., and Forman M.B. Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model. Circulation 80 (1989) 1388-1399
10. Babbitt D.G., Virmani R., Vildibill Jr. H.D., Norton E.D., and Forman M.B. Intracoronary adenosine administration during reperfusion following 3 hours of ischemia: effects on infarct size, ventricular function, and regional myocardial blood flow. Am. J. Heart 120 (1990) 808-818
11. Pitarys II C.J., Virmani R., Vildibill Jr. H.D., Jackson E.K., and Forman M.B. Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation 83 (1991) 237-247
12. Ross A.M., Gibbons R.J., Stone G.W., Kloner R.A., and Alexander R.W. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J. Am. Coll. Cardiol. 45 (2005) 1775-1780
13. Mahaffey K.W., Puma J.A., Barbagelata N.A., DiCarli M.F., Leesar M.A., Browne K.F., et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J. Am. Coll. Cardiol. 34 (1999) 1711-1720
14. Kloner R.A., Forman M.B., Gibbons R.J., Ross A.M., Alexander R.W., and Stone G.W. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 27 (2006) 2400-2405
15. Forman M.B., Vitola J.V., Velasco C.E., Murray J.J., Dubey R.K., and Jackson E.K. Sustained reduction in myocardial reperfusion injury with an adenosine receptor antagonist: possible role of the neutrophil chemoattractant response. J. Pharmacol. Exp. Ther. 292 (2000) 929-938
16. Auchampach J.A., Jin X., Moore J., Wan T.C., Kreckler L.M., Ge Z.D., et al. Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. J. Pharmacol. Exp. Ther. 308 (2004) 846-856
17. Zhao Z.Q., Budde J.M., Morris C., Wang N.P., Velez D.A., Muraki S., et al. Adenosine attenuates reperfusion-induced apoptotic cell death by modulating expression of Bcl-2 and Bax proteins. J. Mol. Cell. Cardiol. 33 (2001) 57-68
18. Schlack W., Schafer M., Uebing A., Schafer S., Borchard U., and Thamer V. Adenosine A2-receptor activation at reperfusion reduces infarct size and improves myocardial wall function in dog heart. J. Cardiovasc. Pharmacol. 22 (1993) 89-96
19. Lasley R.D., Jahania M.S., and Mentzer Jr. R.M. Beneficial effects of adenosine A2A agonist CGS-21680 in infarcted and stunned porcine myocardium. Am. J. Physiol.: Heart Circ. Physiol. 280 (2001) H1660-H1666
20. Jordan J.E., Zhao Z.Q., Sato H., Taft S., and Vinten-Johansen J. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J. Pharmacol. Exp. Ther. 280 (1997) 301-309
21. Glover D.K., Riou L.M., Ruiz M., Sullivan G.W., Linden J., Rieger J.M., et al. Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium. Am. J. Physiol.: Heart Circ. Physiol. 288 (2005) H1851-H1858
22. Linden J. Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol. Sci. 15 (1994) 298-306
23. Auchampach J.A., Ge Z.D., Wan T.C., Moore J., and Gross G.J. The A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia/reperfusion injury in dogs. Am. J. Physiol.: Heart Circ. Physiol. 10 (2003) H607-H613
24. Tracey W.R., Magee W.P., Oleynek J.J., Hill R.J., Smith A.H., Flynn D.M., et al. Novel N6-substituted adenosine 5′-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Am. J. Physiol.: Heart Circ. Physiol. 285 (2003) H2780-H2787
25. Frangogiannis N.G., Smith C.W., and Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc. Res. 53 (2002) 31-47
26. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu. Rev. Pharmacol. Toxicol. 41 (2000) 775-787
27. Bouma M.G., van den Wildenberg F.A., and Buurman W.A. The anti-inflammatory potential of adenosine in ischemia-reperfusion injury: established and putative beneficial actions of a retaliatory metabolite. Shock 8 (1997) 313-320
28. Sullivan G.W., and Linden J. Role of A2A adenosine receptors in inflammation. Drug Dev. Res. 45 (1998) 103-112
29. Sitkovsky M.V., Lukashev D., Apasov S., Kojima H., Koshiba M., Caldwell C., et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 22 (2004) 657-682
30. Hasko G., and Cronstein B.N. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 25 (2004) 33-39
31. Yang Z., Day Y.J., Toufektsian M.C., Ramos S.I., Marshall M., Wang X.Q., et al. Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 111 (2005) 2190-2197
32. Ge Z.D., Wan T.C., and Auchampach J.A. The A3 adenosine receptor agonist Cl-IB-MECA reduces myocardial infarct size in mice when administered during reperfusion: mechanistic studies with A3AR gene 'knock-out' and bone marrow chimeric mice. Circulation 110 (2004) 29
33. van der Hoeven D., and Auchampach J.A. Characterization of expression and function of adenosine receptors in mouse neutrophils. FASEB J. 20 (2006) A249
34. Park S.S., Zhao H., Jang Y., Mueller R.A., and Xu Z. N6-(3-iodobenzyl)-adenosine-5′-N-methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3b. J. Pharmacol. Exp. Ther. 318 (2006) 124-131
35. Jiang J., van Rhee A.M., Chang L., Patchornik A., Ji X.D., Evans P., et al. Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists. J. Med. Chem. 40 (1997) 2596-2608
36. Pugsley M.K. The diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system. Pharmacol. Ther. 93 (2002) 51-75
37. Peart J.N., Gross E.R., and Gross G.J. Opioid-induced preconditioning: recent advances and future perspectives. Vascul. Pharmacol. 42 (2005) 211-218
38. Barron B.A. Opioid peptides and the heart. Cardiovasc. Res. 43 (1999) 13-16
39. Barron B.A. Cardiac opioids. Proc. Soc. Exp. Biol. Med. 224 (2000) 1-7
40. Gross G.J. Role of opioids in acute and delayed preconditioning. J. Mol. Cell. Cardiol. 35 (2003) 709-718
41. Howells R.D., Kilpatrick D.L., Bailey L.C., Noe M., and Udenfriend S. Proenkephalin mRNA in rat heart. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 1960-1963
42. Gross E.R., Hsu A.K., and Gross G.J. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ. Res. 94 (2004) 960-966
43. Gross E.R., Hsu A.K., and Gross G.J. Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphine-induced cardioprotection: role of 12-lipoxygenase. J. Pharmacol. Exp. Ther. 310 (2004) 185-191
44. Gross E.R., Peart J.N., Hsu A.K., Auchampach J.A., and Gross G.J. Extending the cardioprotective window using a novel d-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway. Am. J. Physiol.: Heart Circ. Physiol. 288 (2005) H2744-H2749
45. Zhao Z.Q., Corvera J.S., Halkos M.E., Kerendi F., Wang N.P., Guyton R.A., et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am. J. Physiol.: Heart Circ. Physiol. 285 (2003) H579-H588
46. Laskey W.K. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: a pilot study. Catheter. Cardiovasc. Interv. 65 (2005) 361-367
47. Staat P., Rioufol G., Piot C., Cottin Y., Cung T.T., L'Huillier I., et al. Postconditioning the human heart. Circulation 112 (2005) 2143-2148
48. Yang X.M., Philipp S., Downey J.M., and Cohen M.V. Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res. Cardiol. 100 (2005) 57-63
49. Kin H., Zatta A.J., Lofye M.T., Amerson B.S., Halkos M.E., Kerendi F., et al. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc. Res. 67 (2005) 124-133
50. Heusch G. Postconditioning: old wine in a new bottle?. J. Am. Coll. Cardiol. 44 (2004) 1111-1112